## Min-Shu Hsieh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2679219/publications.pdf

Version: 2024-02-01

66 papers

1,321 citations

393982 19 h-index 395343 33 g-index

68 all docs 68
docs citations

68 times ranked

1970 citing authors

#	Article	IF	Citations
1	Radiomic Values from High-Grade Subtypes to Predict Spread Through Air Spaces in Lung Adenocarcinoma. Annals of Thoracic Surgery, 2022, 114, 999-1006.	0.7	10
2	A radiomics model can distinguish solitary pulmonary capillary haemangioma from lung adenocarcinoma. Interactive Cardiovascular and Thoracic Surgery, 2022, 34, 369-377.	0.5	5
3	Novel Genetic Prognostic Signature for Lung Adenocarcinoma Identified by Differences in Gene Expression Profiles of Low- and High-Grade Histological Subtypes. Biomolecules, 2022, 12, 160.	1.8	4
4	Ciliated muconodular papillary tumorâ€like neoplasm of the nasal cavity with concurrent BRAF V600E and AKT1 E17K mutations. Pathology International, 2022, 72, 264-266.	0.6	0
5	The efficacy of incorporating ultrasound-guided core biopsy into the clinical workflow of indeterminate thyroid tumors. Journal of the Formosan Medical Association, 2022, 121, 2012-2019.	0.8	4
6	Nuclear expression of AFF2 C-terminus is a sensitive and specific ancillary marker for DEK::AFF2 carcinoma of the sinonasal tract. Modern Pathology, 2022, 35, 1587-1595.	2.9	18
7	Solid Attenuation Components Attention Deep Learning Model to Predict Micropapillary and Solid Patterns in Lung Adenocarcinomas on Computed Tomography. Annals of Surgical Oncology, 2022, 29, 7473-7482.	0.7	7
8	The genetic effect and molecular function of the SOCS5 in the prognosis of esophageal squamous cell carcinoma. Journal of Cancer, 2021, 12, 2216-2229.	1.2	1
9	Prediction of micropapillary and solid pattern in lung adenocarcinoma using radiomic values extracted from near-pure histopathological subtypes. European Radiology, 2021, 31, 5127-5138.	2.3	20
10	Sialadenoma Papilliferum. Surgical Pathology Clinics, 2021, 14, 43-51.	0.7	9
11	Risk Stratification in Patients With Follicular Neoplasm on Cytology: Use of Quantitative Characteristics and Sonographic Patterns. Frontiers in Endocrinology, 2021, 12, 614630.	1.5	4
12	Clinicopathological Features and Survival Outcomes of Primary Pulmonary Invasive Mucinous Adenocarcinoma. Cancers, 2021, 13, 4103.	1.7	9
13	SMARCB1(INI1)â€deficient sinonasal adenocarcinoma: Report of a case previously diagnosed as highâ€grade nonâ€intestinalâ€type sinonasal adenocarcinoma. Pathology International, 2021, , .	0.6	1
14	Thoracoscopic Lobectomy Versus Sublobar Resection for pStage I Geriatric Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 777590.	1.3	5
15	Ultrasonographic features for differentiating follicular thyroid carcinoma and follicular adenoma. Asian Journal of Surgery, 2020, 43, 339-346.	0.2	40
16	Salivary Sialadenoma Papilliferum Consists of Two Morphologically, Immunophenotypically, and Genetically Distinct Subtypes. Head and Neck Pathology, 2020, 14, 489-496.	1.3	25
17	Propensity-Matched Analysis Comparing Survival After Sublobar Resection and Lobectomy for cT1N0 Lung Adenocarcinoma. Annals of Surgical Oncology, 2020, 27, 703-715.	0.7	28

#	Article	IF	CITATIONS
19	Molecular subtypes and clinical outcomes to initial systemic treatment in patients with small cell lung cancer Journal of Clinical Oncology, 2020, 38, 9018-9018.	0.8	1
20	Clinical Outcomes of Up-front Surgery Versus Surgery After Induction Chemotherapy for Thymoma and Thymic Carcinoma: A Retrospective Study. Clinical Lung Cancer, 2019, 20, e609-e618.	1.1	11
21	Neutrophil–to–lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors. Anticancer Research, 2019, 39, 5675-5682.	0.5	30
22	Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy. Lung Cancer, 2019, 137, 76-84.	0.9	30
23	Validation of Immunohistochemistry for the Detection of BRAF V600E-Mutated Lung Adenocarcinomas. Cancers, 2019, 11, 866.	1.7	18
24	Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment. European Journal of Surgical Oncology, 2019, 45, 1498-1504.	0.5	9
25	Response to comment on: "Correlation of Tumor Spread through Air Spaces and Clinicopathological Characteristics in Surgically Resected Lung Adenocarcinomas.â€. Lung Cancer, 2019, 132, 151.	0.9	0
26	Primary thyroid hyalinising clear cell carcinoma: a rare variant of salivary gland type carcinoma of the thyroid. Pathology, 2019, 51, 750-752.	0.3	0
27	Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC). Frontiers in Oncology, 2019, 9, 1138.	1.3	17
28	Nuclear immunoreactivity of BLM-s, a proapoptotic BCL-2 family member, is specifically detected in salivary adenoid cystic carcinoma. Human Pathology, 2019, 84, 81-91.	1.1	2
29	Prediction of pleural invasion using different imaging tools in non-small cell lung cancer. Annals of Translational Medicine, 2019, 7, 33-33.	0.7	12
30	Activated interferon- $\hat{I}^3$ (IFN- $\hat{I}^3$ ) pathway associated with clinical benefit to programmed cell death protein-1 (PD-1)/PD ligand 1 (PD-L1)-based therapy in esophageal squamous cell carcinoma (ESCC) Journal of Clinical Oncology, 2019, 37, 67-67.	0.8	0
31	Extraction of radiomic values from lung adenocarcinoma with near-pure subtypes in the International Association for the Study of Lung Cancer/the American Thoracic Society/the European Respiratory Society (IASLC/ATS/ERS) classification. Lung Cancer, 2018, 119, 56-63.	0.9	19
32	Response to Nivolumab as Salvage Therapy in a Patient with Thymic Carcinoma. Journal of Thoracic Oncology, 2018, 13, e36-e39.	0.5	5
33	Correlation of tumor spread through air spaces and clinicopathological characteristics in surgically resected lung adenocarcinomas. Lung Cancer, 2018, 126, 189-193.	0.9	36
34	Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer. Lung Cancer, 2018, 125, 282-290.	0.9	48
35	Circulating Interleukin-6 is Associated with Prognosis and Genetic Polymorphisms of MIR608 in Patients with Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2018, 25, 2449-2456.	0.7	13
36	Oncogenic Function of a KIF5B-MET Fusion Variant in Non-Small Cell Lung Cancer. Neoplasia, 2018, 20, 838-847.	2.3	25

3

#	Article	IF	Citations
37	Solitary pulmonary capillary hemangioma: An under-recognized pulmonary lesion mimicking early lung cancer on computed tomography images. Lung Cancer, 2018, 124, 227-232.	0.9	7
38	Validation of the postneoadjuvant therapy pathological stage of the American Joint Committee on Cancer (AJCC) 8th Edition for predicting outcomes of esophageal squamous cell carcinoma (ESCC) patients receiving neoadjuvant chemoradiotherapy (CRT) followed by esophagectomy Journal of Clinical Oncology, 2018, 36, 138-138.	0.8	0
39	The prognostic impact of neutrophil to lymphocyte ratio in patients with recurrent or metastatic esophageal squamous cell carcinoma receiving immune checkpoint inhibitors Journal of Clinical Oncology, 2018, 36, 69-69.	0.8	o
40	Response to immune checkpoint inhibitors in recurrent/metastatic esophageal squamous cell carcinoma may be affected by tumor site and lesion size Journal of Clinical Oncology, 2018, 36, e16099-e16099.	0.8	0
41	Study of poly-É-caprolactone membranes for pleurodesis. Journal of the Formosan Medical Association, 2017, 116, 880-887.	0.8	4
42	A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population. Lung Cancer, 2017, 103, 82-89.	0.9	47
43	Reevaluation of MAML2 fusion–negative mucoepidermoid carcinoma: a subgroup being actually hyalinizing clear cell carcinoma of the salivary gland with EWSR1 translocation. Human Pathology, 2017, 61, 9-18.	1.1	43
44	Real-world experience of afatinib as a first-line therapy for advanced <i>EGFR</i> mutation-positive lung adenocarcinoma. Oncotarget, 2017, 8, 90430-90443.	0.8	63
45	Expression of Notch Gene and Its Impact on Survival of Patients with Resectable Non-small Cell Lung Cancer. Journal of Cancer, 2017, 8, 1292-1300.	1.2	28
46	Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells. Oncotarget, 2017, 8, 86681-86692.	0.8	11
47	Primary pulmonary hyalinising clear cell carcinoma with mucin production and delayed metastases after 16 years. Pathology, 2016, 48, 518-521.	0.3	14
48	SOX10-positive salivary gland tumors: a growing list, including mammary analogue secretory carcinoma of the salivary gland, sialoblastoma, low-grade salivary duct carcinoma, basal cell adenoma/adenocarcinoma, and a subgroup of mucoepidermoid carcinoma. Human Pathology, 2016, 56, 134-142.	1.1	100
49	Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion–Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations. Journal of Thoracic Oncology, 2016, 11, 1140-1152.	0.5	64
50	Tigroid background in cytology of hyalinizing clear cell carcinoma of the salivary gland. Diagnostic Cytopathology, 2016, 44, 338-341.	0.5	11
51	Epithelial-Myoepithelial Carcinoma of the Salivary Gland Harboring HRAS Codon 61 Mutations With Lung Metastasis. International Journal of Surgical Pathology, 2016, 24, 227-231.	0.4	6
52	The recurrence patterns and post-recurrence survivals in patients with locally advanced esophageal squamous cell carcinoma (ESCC) treated with preoperative paclitaxel/cisplatin-based chemoradiotherapy Journal of Clinical Oncology, 2016, 34, 80-80.	0.8	0
53	Precancerous esophageal epithelia are associated with significantly increased scattering coefficients. Biomedical Optics Express, 2015, 6, 3795.	1.5	13
54	Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. Lung Cancer, 2015, 88, 208-214.	0.9	46

#	Article	IF	CITATIONS
55	Histologic Evolution From Adenocarcinoma to Squamous Cell Carcinoma After Gefitinib Treatment. Annals of Thoracic Surgery, 2015, 99, 316-319.	0.7	32
56	Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinoma. Radiotherapy and Oncology, 2015, 115, 9-15.	0.3	12
57	Postchemoradiotherapy (CRT) pathologic stage classified by American Joint Committee on Cancer (AJCC) staging system to predict prognosis of patients with locally advanced esophageal squamous cell carcinoma (ESCC) Journal of Clinical Oncology, 2015, 33, 158-158.	0.8	0
58	Water-clear cell parathyroid adenoma in a patient with acute pancreatitis. Journal of the Formosan Medical Association, 2014, 113, 872-873.	0.8	9
59	Unique histopathologic features of brain metastases from hepatocellular carcinoma Journal of Clinical Oncology, 2013, 31, 169-169.	0.8	0
60	Vascular endothelial growth factor expression in hepatitis C virus (HCV)-related advanced hepatocellular carcinoma (HCC) compared with hepatitis B virus (HBV)-related advanced HCC Journal of Clinical Oncology, 2013, 31, 4115-4115.	0.8	8
61	Cerebellar anaplastic pilocytic astrocytoma in a patient of neurofibromatosis type-1: Case report and review of the literature. Clinical Neurology and Neurosurgery, 2012, 114, 1027-1029.	0.6	8
62	NUT Midline Carcinoma. International Journal of Surgical Pathology, 2011, 19, 808-812.	0.4	28
63	Myxoid Adrenal Cortical Carcinoma Presenting as Primary Hyperaldosteronism. International Journal of Surgical Pathology, 2011, 19, 803-807.	0.4	25
64	Intravascular Large B cell Lymphoma in Taiwan: An Asian Variant of Non-germinal-center Origin. Journal of the Formosan Medical Association, 2010, 109, 185-191.	0.8	8
65	Hepatic Epithelioid Hemangioendothelioma in Taiwan: A Clinicopathologic Study of Six Cases in a Single Institution Over a 15-Year Period. Journal of the Formosan Medical Association, 2010, 109, 219-227.	0.8	19
66	Combined Pancreatic Endocrine Tumor and Serous Cystadenoma. Journal of the Formosan Medical Association, 2009, 108, 739-745.	0.8	14